Company Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 12:49:36 10/07/2025 pm IST			5-day change	1st Jan Change
7.275 ^EUR	+2.38%		+0.06%	-12.82%

09/07	EVOTEC : Deutsche Bank reiterates its Neutral rating	ZD
26/06	EVOTEC : Warburg Research remains its Buy rating	ZD

Business description: Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Number of employees: 4,766

Sales by Activity: Evotec SE

Fiscal Period: December	2020	2021	2022	2023	2024
Shared R&d	-	-	-	-	61Cr
Just - Evotec Biologics	-	-	-	-	19Cr
EVT Innovate	11Cr	15Cr	20Cr	27Cr	-
EVT Execute	49Cr	61Cr	74Cr	74Cr	-
Transition	2.18Cr	-	-	-	-
Intersegment Elimination	-12Cr	-14Cr	-19Cr	-22Cr	-12.08L

See all business segments

Geographical breakdown of sales: Evotec SE

Fiscal Period: December	2020	2021	2022	2023	2024
USA	25Cr	-	-	46Cr	45Cr
Switzerland	-	-	-	6.49Cr	11Cr
United Kingdom	9.4Cr	-	-	8.64Cr	9.25Cr
Rest of the World	7.77Cr	-	-	9.52Cr	8.23Cr
Germany	4.43Cr	-	-	3.41Cr	3.29Cr
France	3.71Cr	-	-	3.2Cr	1.99Cr
Unallocated	-	-	-	-	1.44Cr

See all geographic segments

Executive Committee: Evotec SE

Manager	Title	Age	Since
Christian Wojczewski CEO	Chief Executive Officer	-	01/07/2024
Paul Robert Hitchin DFI	Director of Finance/CFO	-	01/03/2025
Cord Dohrmann CTO	Chief Tech/Sci/R&D Officer	61	01/09/2010
Volker Braun IRC	Investor Relations Contact	-	-
Bernd Mühlenweg PRN	Corporate Officer/Principal	53	-

See EVOTEC SE governance

Composition of the Board of Directors: Evotec SE

Director	Title	Age	Since
Iris Löw-Friedrich CHM	Chairman	64	15/06/2021
Roland Sackers BRD	Director/Board Member	57	19/06/2019
Constanze Ulmer-Eilfort BRD	Director/Board Member	63	01/06/2021
Camilla Languille BRD	Director/Board Member	42	22/06/2022
Duncan McHale BRD	Director/Board Member	58	10/06/2024
Wesley Wheeler BRD	Director/Board Member	69	10/06/2024
Thomas Hanke BRD	Director/Board Member	-	-

Composition of the Board of Directors

Shareholders: Evotec SE

Name	Equities	%	Valuation
Excalibur Luxco SARL 9.974 %	1,77,30,913	9.974 %	150 M €
Novo Holdings A/S (Investment Company) 8.4 %	1,49,31,858	8.4 %	126 M €
Mubadala Investment Co. (Investment Company) 6.459 %	1,14,81,502	6.459 %	97 M €
T. Rowe Price International Ltd. 4.572 %	81,27,117	4.572 %	69 M €
Black Creek Investment Management, Inc. 3.13 %	55,63,329	3.13 %	47 M €

Name	Equities	%	Valuation
Mubadala Investment Co. (Investment Company) 1.293 %	45,97,701	1.293 %	19 M €
Wellington Trust Co., NA 0.5354 %	19,03,401	0.5354 %	8 M €
Aperio Group LLC 0.4283 %	15,22,664	0.4283 %	6 M €
DCF Advisers LLC 0.2114 %	7,51,579	0.2114 %	3 M €
Morgan Stanley Capital Services LLC 0.0248 %	88,041	0.0248 %	369 772 €

List of EVOTEC SE shareholders

Company details: Evotec SE

Evotec SE

Manfred Eigen Campus Essener Bogen 7

22419, Hamburg

+49 40 560 81 0

http://www.evotec.com

Group companies: Evotec SE

Name	Category and Sector
Evotec (France) SAS Evotec (France) SAS Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (France) SAS is a French company that engages in research and development of physical and natural sciences. The company is based in Toulouse, France. The company was founded in 2014. Pierre Cooremans has been the CEO of the company since 2019.	Miscellaneous Commercial Services
Evotec (UK) Ltd. Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991.	Miscellaneous Commercial Services
Evotec International GmbH Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany.	Miscellaneous Commercial Services
Aptuit (Verona) Srl Aptuit (Verona) Srl Pharmaceuticals: MajorHealth Technology Aptuit (Verona) Srl engages in the provision of integrated drug development solutions. It offers Indigo and Indigo-Select. The company was founded in 2004 and is headquartered in Verona, Italy.	Pharmaceuticals: Major

See all subsidiaries

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVOTEC SE	+2.41%	+0.06%	-24.80%	-71.56%	147.75Cr
LONZA GROUP AG	+0.21%	+1.65%	+10.98%	-0.53%	4.99TCr
BEONE MEDICINES LTD.	+4.59%	+4.65%	+76.91%	+35.47%	3.03TCr
CELLTRION, INC.	+0.34%	+4.26%	+2.73%	+9.59%	2.83TCr
IQVIA HOLDINGS INC.	-1.49%	-1.60%	-23.95%	-26.13%	2.8TCr
EUROFINS SCIENTIFIC SE	+0.17%	-2.00%	+25.24%	-23.20%	1.25TCr
ICON PUBLIC LIMITED COMPANY	-0.69%	-0.19%	-53.54%	-30.93%	1.2TCr
ASCENDIS PHARMA A/S	+4.48%	+1.51%	+28.77%	+87.70%	1.06TCr
QIAGEN N.V.	+0.23%	-1.40%	+16.39%	-6.36%	1.04TCr
TEMPUS AI, INC.	-0.17%	-1.30%	+69.30%	-	1.01TCr
Average	+1.07%	-0.72%	+12.80%	-2.88%	1.94TCr
Weighted average by Cap.	+0.88%	-0.69%	+16.01%	+3.75%